COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery
Open Access
- 10 October 2020
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (4), 1-7
- https://doi.org/10.14218/jcth.2020.00061
Abstract
The severe acute respiratory syndrome corona virus-2 (referred to as SARS CoV2) pandemic had a great impact on public life in general as well as on populations with pre-existing disease and co-morbidities. Liver transplant and immunosuppressant medication predisposes to more severe disease and is often associated with poor outcome. The clinical features, disease course, treatment and process of modulating the immunosuppression is challenging. Here, we describe the clinical presentation, treatment and outcomes in six liver transplant recipients. Out of those six patients, three had mild, one had moderate and one had severe COVID-19, and one was asymptomatic. The immunosuppression minimization or withdrawal was done based upon the clinical severity. Consideration of tocilizumab and/o convalescent plasma as well as antivirals i.e. remdesvir done in severe cases. The routine practice of prophylactic anticoagulation, consideration of repurposed drugs (i.e. teicoplanin and doxycycline), and watchful monitoring of asymptomatic recipients helped to achieve an uneventful recovery.Keywords
This publication has 19 references indexed in Scilit:
- COVID-19 in Liver Transplant Recipients: An Initial Experience From the US EpicenterGastroenterology, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19The New England Journal of Medicine, 2020
- A systematic review of asymptomatic infections with COVID-19Journal of Microbiology, Immunology and Infection, 2020
- COVID-19: An Overview of Worldwide Recommendations for Management of Patients With Liver Diseases or Liver TransplantationClinical Gastroenterology and Hepatology, 2020
- COVID-19 in solid organ transplant recipients: Initial report from the US epicenterAmerican Journal of Transplantation, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Change in antibiotic regimen for emerging multidrug resistance in nosocomial ascitic fluid infectionHepatology International, 2019
- Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and DiseaseFrontiers in Immunology, 2019
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)Online Journal of Public Health Informatics, 2016
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008